ArticleBMC complementary medicine and therapies2025
Identification of quality markers and mechanisms of Anzi Tiaochong Fang in the treatment of antiphospholipid syndrome-related recurrent pregnancy loss: chemical analysis, network pharmacology, and in vitro approaches.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gu Ben An Tai decoction combined with dydrogesterone for early threatened abortion secondary to spleen and kidney deficiency: a retrospective observational study.Contraception and reproductive medicine · 2026Article
- Anzi Tiaochong Tang inhibits trophoblast ferroptosis via the METTL14/m6A/SLC39A14 axis in recurrent spontaneous abortion.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionAnzi Tiaochong Fang (ATF) is a traditional Chinese medicine (TCM) Fangji widely used to treat antiphospholipid syndrome-related recurrent pregnancy loss (APS-RPL). This study aimed to identify the quality markers and elucidate the mechanisms of ATF in treating APS-RPL.
methodsChemical, network pharmacology, and in vitro verification were employed to identify quality markers and mechanisms of ATF. HPLC-MS/MS was used to identify and quantify ATF compounds. APS-RPL targets were identified using databases such as HERB, similarity ensemble approach, PharmMapper, Swiss Target Prediction, Gene Expression Omnibus, Genecards, and DisGeNET. GO and Reactome analyses were conducted using KOBAS-i. In vitro verification was performed using CCK-8, FDA staining, and ELISA.
resultsThis study identified 23 compounds and 942 targets, including 132 APS-RPL targets and 42 targets between ATF and APS-RPL. GO analysis demonstrated significant enrichment in cytokine-mediated signaling pathway, positive regulation of angiogenesis, response to hypoxia, inflammatory response, and platelet degranulation. Reactome analysis indicated significant enrichment in Immune System, Cytokine Signaling in the Immune system, Signaling by Interleukins, Platelet activation, signaling and aggregation, and Signaling by VEGF. Core targets identified included VEGFA, ALB, TNF, IL-6, and STAT3, with liquiritigenin, nobiletin, ginsenoside Rb1, and astragalin identified as quality markers. In vitro experiments demonstrated that ATF promoted HTR-8/SVneo cell viability, significantly reduced TNF-α and IL-1β levels, and upregulated IL-6.
conclusionsThese findings contribute to the identification and quantification of potential quality markers and elucidate the molecular mechanisms of ATF, thereby supporting its therapeutic potential in the treatment of APS-RPL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.